We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD) is a rare autoimmune disorder where the body's immune system mistakenly attacks myelin, the protective covering of nerve fibers, leading to neurological symptoms.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
